James McLaughlin

James McLaughlin is president, CEO and co-founder of Gemini Therapeutics, and has led the company since its inception in 2015. James has a background in business, gene therapy, ophthalmic drug development and venture capital. Most recently, James was one of the co-founders of Voyager Therapeutics (NASDAQ: VYGR), a gene therapy company focused on CNS disorders. He previously worked at Third Rock Ventures and Advanced Technology Ventures, where he focused on rare disease therapeutics and at Ora, a Massachusetts-based CRO, where he focused on retinal drug development. James received an MBA from Harvard University and his undergraduate degree from Colby College.